Syntegon achieves record 2025 results as pharmaceutical innovation drives 22% growth

GERMANY—Syntegon has announced record financial results for fiscal year 2025, driven by strong execution across its pharmaceutical, biotech, and food manufacturing divisions.

The company grew revenue by 10% to EUR 1.75 billion (USD1.91 billion) while substantially improving profitability and cash generation.

Strong financial performance delivers visibility into 2026

CEO Torsten Türling highlighted the company’s transformation into a strategic lifecycle partner, noting that operational excellence now underpins sustainable, long-term growth.

The financial results reflect this strategy: EBITDA jumped 27% to EUR 282 million (USD 307 million), pushing margins up 210 basis points to 16.1%.

Meanwhile, free cash flow surged 51% to EUR 196 million (USD 214 million), fueled by disciplined working capital management and lean capital expenditure.

Order intake reached EUR 1.86 billion (USD 2.03 billion), providing strong visibility into 2026.

CFO Eros Carletti credited this performance to meaningful improvements across all key metrics while maintaining disciplined capital allocation.

Margin expansion stemmed from higher volumes in attractive segments, persistent cost discipline, and improved project execution.

Critically, Syntegon’s rebalanced global manufacturing footprint and newly established engineering hub in India have structurally strengthened profitability.

Strategic investments position company for growth

The company deployed targeted capital toward capacity expansion and innovation.

It opened a Business Excellence Center in Stuttgart and launched a new Pharma Solid factory in Fellbach, Germany.

Simultaneously, Syntegon invested EUR 56 million (USD 61 million) in R&D, developing next-generation production line solutions to address evolving customer needs.

Pharma Division Accelerates on Innovation Wave

Syntegon’s pharma business accelerated growth, with sales rising 22% year over year.

The division benefits from expanding biotech innovation and an increasingly complex injectable therapies pipeline, factors that drive demand for integrated, technologically advanced solutions.

The company’s acquisition of Telstar strategically broadened its end-to-end pharmaceutical portfolio and delivered results ahead of plan in its first integration year.

The company’s marquee innovation, SynTiso, represents the world’s first gloveless high-speed filling line for liquid pharmaceuticals.

The breakthrough technology eliminates contamination risks while boosting production efficiency, already generating significant orders from major pharmaceutical manufacturers.

Food and Service Segments Show Sustained Momentum

Syntegon’s food business gained traction from rapid customer adoption of its newly launched SVX product platform, which stands out for speed, flexibility, and sustainability performance.

The service business continues its solid expansion as customers seek performance upgrades for existing lines and advanced support solutions.

Sustainability recognition and future outlook

Syntegon earned the EcoVadis Platinum Medal in 2025, positioning itself among the world’s leading companies in sustainability performance.

Looking ahead, the company plans to expand aggressively in the United States and systematically unlock the service potential of its industry-leading installed base.

With Business Plan 2030 as its roadmap, Syntegon aims to strengthen innovation leadership, scale its service operations, and pursue its next phase of operational excellence initiatives.